Bencyclane Fumarate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 329309

CAS#: 14286-84-1(fumarate)

Description: Bencyclane Fumarate, also known as Halidor, is a vasodilator agent found to be effective in a variety of peripheral circulation disorders. Bencyclane Fumarate's mechanism may involve blocking of calcium channels.


Price and Availability

Size
Price

Size
Price

Size
Price

Bencyclane Fumarate (Halidor) is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 329309
Name: Bencyclane Fumarate
CAS#: 14286-84-1(fumarate)
Chemical Formula: C23H35NO5
Exact Mass: 405.2515
Molecular Weight: 405.535
Elemental Analysis: C, 68.12; H, 8.70; N, 3.45; O, 19.73


Synonym: Bencyclane Fumarate; Halidor; Angiociclan; Angiodel; Diacyclan; Hemoflux;

IUPAC/Chemical Name: 3-((1-benzylcycloheptyl)oxy)-N,N-dimethylpropan-1-amine fumarate

InChi Key: LSTKNZAMFRGXCG-WLHGVMLRSA-N

InChi Code: InChI=1S/C19H31NO.C4H4O4/c1-20(2)15-10-16-21-19(13-8-3-4-9-14-19)17-18-11-6-5-7-12-18;5-3(6)1-2-4(7)8/h5-7,11-12H,3-4,8-10,13-17H2,1-2H3;1-2H,(H,5,6)(H,7,8)/b;2-1+

SMILES Code: CN(CCCOC1(CC2=CC=CC=C2)CCCCCC1)C.O=C(O)/C=C/C(O)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#

2179-37-5 (Bencyclane)
14286-84-1 (Bencyclane Fumarate)


References

1: Barut I, Tarhan OR, Kapucuoglu N, Sutcu R, Akdeniz Y. Effect of bencyclane fumarate on intestinal ischaemia reperfusion injury. ANZ J Surg. 2008 Jun;78(6):476-81. doi: 10.1111/j.1445-2197.2008.04358.x. PubMed PMID: 18522569.

2: Fujioka K, Kurosaki Y, Sato S, Noguchi T, Noguchi T, Yamahira Y. Biopharmaceutical study of inclusion complexes. I. Pharmaceutical advantages of cyclodextrin complexes of bencyclane fumarate. Chem Pharm Bull (Tokyo). 1983 Jul;31(7):2416-23. PubMed PMID: 6640805.

3: Cavallini L, Lucchetti G. [Effect of bencyclane fumarate on brain metabolism in the rat--in vitro study]. Boll Chim Farm. 1977 Aug;116(8):473-83. French. PubMed PMID: 921852.

4: Hockwin O, Korte I, Breuer R, Schmidt G, Rast-Czyborra F. [In vitro incubation of lenses. Model for testing substrate utilization of substances of the energy metabolism, demonstrated with bencyclane-hydrogen-fumarate (author's transl)]. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1978 Aug 16;207(3):169-80. German. PubMed PMID: 309736.

5: Hockwin O, Korte I, Loth C, Ohrloff C, Fuss R, Schmidt G. Action of bencyclane-hydrogen-fumarate on the carbohydrate metabolism of bovine lens homogenates. Arzneimittelforschung. 1977 Jul;27(7):1417-20. PubMed PMID: 578465.

6: Schumann J. [The effect of bencyclane hydrogen fumarate (Fludilate) on the adhesion of tumor cells in vivo and in vitro]. Fortschr Med. 1976 Sep 16;94(26):1429-32. German. PubMed PMID: 61934.

7: Mohri Z, Yasuda T, Kawahara K, Shono F, Yoshitake A. Radioimmunoassay of bencyclane in human serum. J Pharmacobiodyn. 1985 Mar;8(3):227-33. PubMed PMID: 4009414.

8: Bock PR. A contribution to the pharmacokinetics of bencyclane (Fludilat) in man. Int J Clin Pharmacol Biopharm. 1976 Jun;13(4):246-52. PubMed PMID: 965131.

9: Gawrych Z, Szyszko E. [Coulometric determination of bencyclane hydrogen fumarate in substance and tablets]. Acta Pol Pharm. 1978;35(6):695-6. Polish. PubMed PMID: 742400.

10: Gielsdorf W, Settlage JA, Jaeger H. Quantitative determination of bencyclane in human plasma by capillary gas chromatography/chemical ionization mass spectrometry. Arzneimittelforschung. 1984;34(3):290-2. PubMed PMID: 6539608.

11: Magdalan J, Antończyk A, Kochman K, Porebska B. [Severe bencyctane intoxication--a case report]. Przegl Lek. 2007;64(4-5):301-3. Polish. PubMed PMID: 17724891.

12: Berezhnaya SV, Yakupov EZ. [The neuroprotective therapy of outpatient treatment of chronic cerebral ischemia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(6):48-52. Russian. PubMed PMID: 26356397.

13: Kimura K, Nagata A, Miyawaki H. The metabolism of benzyclane [1-benzyl-1-(3-N,N-dimethylaminopropoxy)cycloheptane] in rat and man. Xenobiotica. 1979 Feb;9(2):119-27. PubMed PMID: 433310.

14: Koçak R, Başlamişli F, Güvenç B, Tamer L, Aikimbaev KS, Isbir T. Bencyclane as an anti-sickling agent. Br J Haematol. 1996 Feb;92(2):329-31. PubMed PMID: 8602994.

15: Yang S, Wang X, Guo H, Dong G, Peng B, Qiu J, Zhang R, Shi Y. Broadband near-infrared emission in Tm3+-Dy3+ codoped amorphous chalcohalide films fabricated by pulsed laser deposition. Opt Express. 2011 Dec 19;19(27):26529-35. doi: 10.1364/OE.19.026529. PubMed PMID: 22274237.